Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis - PubMed (original) (raw)
doi: 10.1007/s10048-004-0193-0. Epub 2004 Oct 2.
Margaret A Pericak-Vance, Jonathan L Haines, Nailah Siddique, Diane McKenna-Yasek, Wu-Yen Hung, Peter Sapp, Coy I Allen, Wenjie Chen, Betsy Hosler, Ann M Saunders, Lisa M Dellefave, Robert H Brown, Teepu Siddique
Affiliations
- PMID: 15657798
- DOI: 10.1007/s10048-004-0193-0
Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis
Yi-Ju Li et al. Neurogenetics. 2004 Dec.
Abstract
Apolipoprotein E (APOE) is a confirmed risk factor for Alzheimer disease. APOE is also involved in several other neurodegenerative disorders, including Parkinson disease and multiple sclerosis. Previous studies of amyotrophic lateral sclerosis (Lou Gehrig disease, ALS) have investigated the effect of APOE on the risk of developing ALS, age at onset, site of onset, and duration of the disease. The results have been inconsistent, possibly due to small sample sizes and complete reliance on case-control data. No family-based association studies were performed. To address these limitations, we investigated the relationship between APOE functional polymorphisms and age at onset of ALS in a large set of 508 families. We treated age at onset as a quantitative trait and performed family-based association analysis using the TDTQ5 method. APOE-2 is protective against earlier onset (P =0.001) with an average age at onset of APOE-2 carriers approximately 3 years later than that of non-APOE-2 carriers. Similar to our previous report, we did not find APOE associated with ALS risk. Our findings suggest that APOE may express its strongest effect through age at onset rather than on risk.
Similar articles
- Lack of association between apolipoprotein E genotype and sporadic amyotrophic lateral sclerosis.
Siddique T, Pericak-Vance MA, Caliendo J, Hong ST, Hung WY, Kaplan J, McKenna-Yasek D, Rimmler JB, Sapp P, Saunders AM, Scott WK, Siddique N, Haines JL, Brown RH. Siddique T, et al. Neurogenetics. 1998 Mar;1(3):213-6. doi: 10.1007/s100480050031. Neurogenetics. 1998. PMID: 10737125 - Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis.
Mui S, Rebeck GW, McKenna-Yasek D, Hyman BT, Brown RH Jr. Mui S, et al. Ann Neurol. 1995 Sep;38(3):460-3. doi: 10.1002/ana.410380318. Ann Neurol. 1995. PMID: 7668834 - Does apolipoprotein E genotype modify the clinical expression of ALS?
Jawaid A, Poon M, Strutt AM, Rice LK, McDowell EJ, Salamone AR, Qureshi SU, Simpson E, Appel SH, York MK, Schulz PE. Jawaid A, et al. Eur J Neurol. 2011 Apr;18(4):618-24. doi: 10.1111/j.1468-1331.2010.03225.x. Epub 2010 Sep 28. Eur J Neurol. 2011. PMID: 20880000 - Amyotrophic lateral sclerosis as a complex genetic disease.
Simpson CL, Al-Chalabi A. Simpson CL, et al. Biochim Biophys Acta. 2006 Nov-Dec;1762(11-12):973-85. doi: 10.1016/j.bbadis.2006.08.001. Epub 2006 Aug 5. Biochim Biophys Acta. 2006. PMID: 16973338 Review. - Apolipoprotein E and neuromuscular disease: a critical review of the literature.
Bedlack RS, Strittmatter WJ, Morgenlander JC. Bedlack RS, et al. Arch Neurol. 2000 Nov;57(11):1561-5. doi: 10.1001/archneur.57.11.1561. Arch Neurol. 2000. PMID: 11074787 Review.
Cited by
- Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs.
Leon C, Hill JS, Wasan KM. Leon C, et al. Pharm Res. 2005 Oct;22(10):1578-88. doi: 10.1007/s11095-005-6306-0. Epub 2005 Sep 22. Pharm Res. 2005. PMID: 16180116 Review. - Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer's disease and frontotemporal dementia.
Agosta F, Vossel KA, Miller BL, Migliaccio R, Bonasera SJ, Filippi M, Boxer AL, Karydas A, Possin KL, Gorno-Tempini ML. Agosta F, et al. Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):2018-22. doi: 10.1073/pnas.0812697106. Epub 2009 Jan 22. Proc Natl Acad Sci U S A. 2009. PMID: 19164761 Free PMC article. - Clinical genetics of amyotrophic lateral sclerosis: what do we really know?
Andersen PM, Al-Chalabi A. Andersen PM, et al. Nat Rev Neurol. 2011 Oct 11;7(11):603-15. doi: 10.1038/nrneurol.2011.150. Nat Rev Neurol. 2011. PMID: 21989245 Review. - Diabetes Mellitus and Amyotrophic Lateral Sclerosis: A Systematic Review.
Ferri L, Ajdinaj P, Rispoli MG, Carrarini C, Barbone F, D'Ardes D, Capasso M, Muzio AD, Cipollone F, Onofrj M, Bonanni L. Ferri L, et al. Biomolecules. 2021 Jun 10;11(6):867. doi: 10.3390/biom11060867. Biomolecules. 2021. PMID: 34200812 Free PMC article. - Mechanism-based treatments for Alzheimer's disease.
Davies P, Koppel J. Davies P, et al. Dialogues Clin Neurosci. 2009;11(2):159-69. doi: 10.31887/DCNS.2009.11.2/pdavies. Dialogues Clin Neurosci. 2009. PMID: 19585951 Free PMC article. Review.
References
- Am J Hum Genet. 2000 Jan;66(1):279-92 - PubMed
- Am J Hum Genet. 2003 Aug;73(2):383-9 - PubMed
- Am J Hum Genet. 2001 Apr;68(4):1065-7 - PubMed
- Am J Hum Genet. 2002 Jan;70(1):251-6 - PubMed
- J Neurol Sci. 1998 Oct;160 Suppl 1:S25-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous